Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
Last trade$15.64
Day change+$0.11 (+0.71%)
Day range$15.27 – $16.01
Volume406,250
Market cap$4.24B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for STVN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for STVN.
Recent news
Company coverage with links to the original publishers.
Stevanato Group (STVN) reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.17, with revenues of $375.28 million exceeding expectations by 3.14%. However, the stock has underperformed the S&P 500 by 12.1% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Meanwhile, peer company 4D Molecular Therapeutics is expected to report a quarterly loss of $1.04 per share.
United Therapeutics shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on UTHR's patent for inhaled treprostinil, potentially restricting competition for UTHR's Tyvaso products. However, the stock faces headwinds as consensus EPS estimates were revised 1.4% lower over the past 30 days, and the company is expected to report declining earnings and flat revenue growth.
electroCore (ECOR) shares surged 6.9% to $11.38 following raised 2026 revenue-growth outlook of over 30% and improved operating performance. Q2 revenues increased 28% YoY to $9.5 million with narrowed adjusted EBITDA losses. However, the stock carries a Zacks Rank #3 (Hold) as earnings estimate revisions have remained flat over the past 30 days.
The global pharmaceutical glass packaging market is projected to grow from USD 5.32 billion in 2025 to USD 12.39 billion by 2035, with a CAGR of 8.82%. Growth is driven by rising demand for injectables, biologics, and GLP-1 therapies, alongside stringent EU regulatory requirements for sustainability and anti-counterfeiting measures. Europe, particularly Germany, is expected to be a major growth contributor.
The European market for glass prefilled syringes and glass vials packaging equipment is projected to grow from USD 283.30 billion in 2025 to USD 389.13 billion by 2034, driven by rising demand for injectable biologics, sterile drug delivery systems, and advanced healthcare infrastructure.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jun 11, 2026
€0.054
Jul 29, 2026
recurring
Jun 5, 2025
€0.054
Jul 17, 2025
recurring
Jun 4, 2024
€0.053
Jul 15, 2024
recurring
Jun 7, 2023
€0.054
Jul 17, 2023
recurring
Jun 13, 2022
€0.051
Jul 13, 2022
recurring
Stock splits
Historical share-structure events and their execution dates.